Video Programs

Dr. Bose discusses the REALISE trial and its implications for ruxolitinib dosing strategy, particularly in terms of safety and efficacy, and the purpose of this dosing strategy assessment in this patient population.

Dr. Bose shares his experience in managing anemia in patients with myelofibrosis, including current strategies used in his practice and the effect of the degree of anemia on treatment approach.

Dr. Bose discusses the impact of ruxolitinib on the overall survival of patients with MF and briefly reviews the COMFORT I and COMFORT II trials that led to the approval of ruxolitinib.

Dr. Bose explains the treatment goals for patients with MF, including the role of overall survival (OS) as a treatment goal.

Dr. Bose discusses the key diagnostic findings that support the diagnosis of myelofibrosis (MF) in this patient and reviews the treatment options and selection in accordance with the treatment guidelines for MF.

Dr. Bose reviews the case of a 68-year-old woman with myelofibrosis presenting with mild fatigue, anemia, splenomegaly, and intermediate-2/high risk disease based on prognostic scoring systems.

Dr. Bose discusses the potential role of other treatment modalities, such as ruxolitinib combination therapies or novel agents, in managing this patient's myelofibrosis and anemia, including the emerging treatment options that may be relevant to this case.

Dr. Bose discusses the potential adverse effects associated with ruxolitinib therapy and how they should be managed in this patient, with a focus on addressing the risk of anemia and other hematologic adverse effects.

The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.

Dr Pal discusses the study design and results of the KEYNOTE-564 trial, and Benjamin Gerendash, MSN, RN, AGACNP-BC, discusses the management of adverse events associated with pembrolizumab.

In this concluding segment, Dr. Shore will share clinical pearls and practical insights regarding the optimal management of patients with metastatic hormone-sensitive prostate cancer.

Dr. Shore will highlight the importance of a multidisciplinary approach in the management of patients with mHSPC and the roles of various healthcare professionals in providing comprehensive care.

Dr. Shore will discuss the factors that guide treatment choices for mHSPC patients with a high disease burden and comorbidities.

In this segment, Dr. Shore will review the findings of several pivotal Phase 3 trials evaluating the efficacy of various treatments in metastatic hormone-sensitive prostate cancer patients, including the MAGNITUDE, PROpel, and TALAPRO-2 trials, among others.

Dr. Shore will provide an overview of the Phase 3 ARASENS trial, which evaluated the efficacy of the androgen receptor inhibitor darolutamide in combination with androgen deprivation therapy (ADT) and docetaxel in hormone-sensitive prostate cancer patients. He will discuss the potential benefits of this combination in patients with high tumor burden mHSPC.

Dr. Shore will explore the evidence supporting treatment intensification through combining or sequencing therapies in metastatic prostate cancer. He will discuss the potential benefits and downsides of this approach, as well as which patients may benefit from an intensified treatment strategy.

In this segment, Dr. Shore will offer an overview of current treatment options for metastatic hormone-sensitive prostate cancer (mHSPC), as outlined in the NCCN Guidelines for Prostate Cancer. He will discuss patient factors that guide the selection of therapeutic agents or combination therapies.

Dr. Shore will provide his initial impressions of the patient case, including an assessment of the patient's risk level and how this influences clinical decision-making.

The panel gives an overview of adjuvant immunotherapy options for patients with renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, presents the case of a 48-year-old man with renal cell carcinoma, and Rana R. McKay, MD, discusses how she discusses risk of recurrence with patients.

The final segment explores the potential role of axatilimab, a novel agent, in the management of refractory cGvHD, highlighting its mechanism of action and potential efficacy compared to existing treatment options.

Yi-Bin Chen, MD, proposes a strategy to enhance patients' quality of life by utilizing virtual monitoring as an alternative to requiring patients to travel to a transplant center, which includes regular remote assessments of blood work, such as liver function tests, lipid panels, and immunoglobulin levels.

A medical expert delves into various aspects of second-line therapies, including dose reductions, potential adverse reactions, and the possibility of transfusions, all of which are important considerations when managing patients on second-line treatments.

Arvind Dasari, MD, explores the adverse event profile of Fruquintinib, highlighting its apparent tolerability, while emphasizing the importance of gathering real-world data to further assess the adverse event profile of this medication in clinical practice.

Medical professionals provide background on the FRESCO-2 trial, which compared Fruquintinib to placebo in patients with heavily pretreated metastatic colorectal cancer. The trial enrolled patients who had exhausted all standard treatment options, including cytotoxic chemotherapy, targeted therapies, anti-VEGF agents, and BRAF inhibitors for those with BRAF mutations.

Anne O’Dea, MD, discusses factors that contribute to second-line treatment selection and offers clinical insights on improving outcomes for patients being treated for breast cancer.

Expert perspectives on safety data from the EMERALD subgroup analysis, highlighting endocrine therapy–related adverse effects and supportive care strategies.

Dr O’Dea provides an overview of the EMERALD trial investigating elacestrant in patients with ER+/HER2- advanced breast cancer and discusses subgroup analysis data and their clinical implications.